Riera-Mestre Antoni, Becattini Cecilia, Giustozzi Michela, Agnelli Giancarlo
Internal Medicine, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat Barcelona Spain.
Thromb Res. 2014 Dec;134(6):1265-71. doi: 10.1016/j.thromres.2014.10.004. Epub 2014 Oct 13.
The role of thrombolysis in hemodynamically stable patients with acute pulmonary embolism (PE) remains controversial. We performed a meta-analysis of randomized trials to assess the effect of thrombolysis in these patients.
We searched MEDLINE and EMBASE for randomized studies comparing thrombolysis and heparin for the initial treatment of hemodynamically stable PE patients. Pooled odds ratios (OR) and 95% confidence intervals (CI) were calculated. NNH to cause a major bleeding (MB) or an intracranial hemorrhage (ICH) and NNT to avoid one death were also calculated.
Eleven studies (1833 patients) were included seven with rt-PA, three with tenecteplase and one with urokinase. Patients randomized to thrombolysis had a significant increased risk for MB (5.9% vs 1.9%; OR 2.83, 95% CI 1.68-4.76, I2 18.7%) and an increased risk for ICH (1.74% versus 0.6%; OR 2.36, 95% CI 0.98-5.71, I2 0%) and for fatal bleeding (1.3% versus 0.54%; OR 1.84, 95% CI 0.73-4.61, I2 0%). A not-significant reduction for all-cause death (1.74% vs 2.51%; OR 0.68, 95% CI 0.37-1.26, I2 0%) and a significant reduction for recurrent PE (1.1% vs 2.5%; OR 0.44, 95% CI 0.21-0.92, I2 0%) in favor of thrombolysis compared with heparin was found. NNH to cause a MB or an ICH were 27 and 91 patients, respectively. NNT to avoid one death was 125 patients.
Due to increased risk for MB and ICH with no evidence of reduction in mortality, thrombolysis should not be used for most normotensive PE patients.
溶栓治疗在血流动力学稳定的急性肺栓塞(PE)患者中的作用仍存在争议。我们进行了一项随机试验的荟萃分析,以评估溶栓治疗对这些患者的效果。
我们检索了MEDLINE和EMBASE数据库,查找比较溶栓治疗与肝素用于血流动力学稳定的PE患者初始治疗的随机研究。计算合并比值比(OR)和95%置信区间(CI)。还计算了导致大出血(MB)或颅内出血(ICH)的需治疗人数(NNH)以及避免一例死亡的需治疗人数(NNT)。
纳入了11项研究(1833例患者),其中7项使用重组组织型纤溶酶原激活剂(rt-PA),3项使用替奈普酶,1项使用尿激酶。随机接受溶栓治疗的患者发生MB的风险显著增加(5.9%对1.9%;OR 2.83,95% CI 1.68 - 4.76,I² 18.7%),发生ICH的风险增加(1.74%对0.6%;OR 2.36,95% CI 0.98 - 5.71,I² 0%),发生致命性出血的风险增加(1.3%对0.54%;OR 1.84,95% CI 0.73 - 4.61,I² 0%)。与肝素相比,溶栓治疗使全因死亡有非显著降低(1.74%对2.51%;OR 0.68,95% CI 0.37 - 1.26,I² 0%),使复发性PE显著降低(1.1%对2.5%;OR 0.44,95% CI 0.21 - 0.92,I² 0%)。导致MB或ICH的NNH分别为27例和91例患者。避免一例死亡的NNT为125例患者。
由于MB和ICH风险增加且无死亡率降低的证据,大多数血压正常的PE患者不应使用溶栓治疗。